Drug Approval | August 28, 2023
Briefs: Granules India
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Oteseconazole Capsules were found to be safe and more effective than fluconazole
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Subscribe To Our Newsletter & Stay Updated
